Pretty Good For Pharma - Avis employé Senior Sales Representative Merck

3,0
9 sept. 2010
Recommande
Approbation du PDG
Perspective commerciale

Avantages

I think the salaries are on the high end for reps compared to other companies. I think they are as good as or better than any pharma company when it comes to allowing you to run your business (within limits). Anyone who has been a pharma rep will understand this statement.

Inconvénients

Merck has lost most of it's panache. It used to be rather prestigious to be a Merck rep. It no longer is. Merck has had legal trouble, which lost them a lot of respect and trust. They have also had trouble with products in the media (negatively). They have had 3 or 4 layoffs in as many years. Management moves around a lot. The purchase of Schering Plough resulted in a big layoff in spite of employees being told most of the layoffs would come from the Schering side. The year prior to the purchase was riddled with unkept promises. Overall, it is not very safe to be a pharma rep these days, for any company. Downsizing is a way of life for them all. Merck, as well as other pharma companies, are hiring third parties to decide how the cuts will be made. There is no consideration of tenure or performance. They are cutting based on geography, and the position you hold. Do not expect loyalty for a job well done.

Découvrez plus d’avis sur Merck

5,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Excellent company to work with.

Inconvénients

No cons encountered so far

4,0
30 juin 2026
Recommande
Approbation du PDG
Perspective commerciale

Avantages

Great benefits like medical/dentist/vision, pension, stock option, 401k match. Co workers are excellent, pretty good on site symposiums, lot of diversity clubs/activities. Innovation is extremely welcomed. Diversity in research portfolio. AI/ML is heavily invested to make databases more efficient.

Inconvénients

Micro managing, especially within the biologics department, potentially others. Promotions are limited, and pay bump is poor. Company invests too much in buying companies rather than keeping talent - lay offs let go of great talented people. Merck is afraid of investing into exploratory biology and doesn’t take risk - they even admit they would rather see other companies clinical data or R&D data rather than taking a risk. Although it’s slow going in building new software, current databases are slow and needs much improvement. Extremely poor work/life balance.

Voir les avis par: Utile|Évaluation|Date|Tout